FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.

Shi Y, Ma Z, Cheng Q, Wu Y, Parris AB, Kong L, Yang X. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. Biochim Biophys Acta Mol Cell Res. 2021 01; 1868(1):118877.

View in: PubMed

authors with profiles

Xiaohe Yang

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support